| PST2774 |
| (5alpha)-Androstane-3,6,17-trione 3-[O-(2-aminoethyl)oxime] |
| (CAS 203737-93-3) |
 |
| Description： |
Istaroxime(PST2744) is a positive inotropic agent that mediates its action through inhibition of sodium/potassium adenosine triphosphatase (Na+/K+ ATPase).
Istaroxime is a positive inotropic agent that mediates its action through inhibition of sodium/potassium adenosine triphosphatase (Na+/K+ ATPase). Istaroxime is an investigational drug originally patented and developed by the italian pharmaceutical company Sigma-Tau. Istaroxime is now under development for treatment of acute decompensated heart failure by CVie Therapeutics.
|
| Product No. |
KT00734 |
| Product Name |
PST2774 |
| Synonyms |
Istaroxime |
| Formal Name |
(5alpha)-Androstane-3,6,17-trione 3-[O-(2-aminoethyl)oxime] |
| CAS Number |
203737-93-3 |
| Molecular Formula |
C21H32N2O3 |
| Formula Weight |
360.49 |
| Formulation |
A crystalline solid |
| Purity |
98%min |
| Stability |
2 years |
| Storage |
-20°C |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500 |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
Istaroxime hydrochloride
Rostafuroxin
|
|
